COPENHAGEN, JULY 01 2018 – AntibioTx, a clinical stage, pharmaceutical company targeting antimicrobial infections and microbiome-related disorders today announced that the company has expanded the management team with Umar Hayat, Ph.D. as VP of CMC and Supply Chain.
Dr. Morten Sommer, Chief Scientific Officer of AntibioTx commented: ”As the company continues to expand into new areas the role of CMC becomes increasingly important for our success. We are delighted to have engaged with such a capacity as Umar and are looking very much forward working with him on the team”
Umar Hayat, Ph.D. will be the VP of CMC and Supply Chain at AntibioTx and will, in particular, be responsible for the late-stage clinical part of CMC. Dr. Hayat has more than 18 years of experience in pharmaceutical development, manufacturing and supply chain. He held senior level positions with Relypsa, Anacor and Transcept Pharmaceuticals. Played a pivotal role in the CMC development and commercialization of Veltassa® (USA and EU), a treatment for hyperkalemia, Intermezzo® for MOTN insomnia, Kerydin® for onychomycosis, and Eucrisa® for atopic dermatitis. Umar received his Ph.D. in process engineering from INP-Toulouse, France and Post-Doctoral Fellowship from Ecole Polytechnique de Montreal, Canada.
This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of AntibioTx A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.
